Benjamin A Katchman1, Diego Chowell1, Garrick Wallstrom1, Allison F Vitonis2, Joshua LaBaer1, Daniel W Cramer2, Karen S Anderson3. 1. Virginia G. Piper Center for Personal Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA. 2. Department of Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA. 3. Virginia G. Piper Center for Personal Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA. Electronic address: Karen.Anderson.1@asu.edu.
Abstract
Objective The purpose of this study was to identify a panel of novel serum tumor antigen-associated autoantibody (TAAb) biomarkers for the diagnosis of high-grade serous ovarian cancer. METHODS: To detect TAAb we probed high-density programmable protein microarrays (NAPPA) containing 10,247 antigens with sera from patients with serous ovarian cancer (n=30 cases/30 healthy controls) and measured bound IgG. We identified 735 promising tumor antigens and evaluated these with an independent set of serous ovarian cancer sera (n=30 cases/30 benign disease controls/30 healthy controls). Thirty-nine potential tumor autoantigens were identified and evaluated using an orthogonal programmable ELISA platform against a total of 153 sera samples (n=63 cases/30 benign disease controls/60 healthy controls). Sensitivities at 95% specificity were calculated and a classifier for the detection of high-grade serous ovarian cancer was constructed. RESULTS: We identified 11-TAAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) that distinguished high-grade serous ovarian cancer cases from healthy controls with a combined 45% sensitivity at 98% specificity. CONCLUSION: These are potential circulating biomarkers for the detection of serous ovarian cancer, and warrant confirmation in larger clinical cohorts.
Objective The purpose of this study was to identify a panel of novel serum tumor antigen-associated autoantibody (TAAb) biomarkers for the diagnosis of high-grade serous ovarian cancer. METHODS: To detect TAAb we probed high-density programmable protein microarrays (NAPPA) containing 10,247 antigens with sera from patients with serous ovarian cancer (n=30 cases/30 healthy controls) and measured bound IgG. We identified 735 promising tumor antigens and evaluated these with an independent set of serous ovarian cancer sera (n=30 cases/30 benign disease controls/30 healthy controls). Thirty-nine potential tumor autoantigens were identified and evaluated using an orthogonal programmable ELISA platform against a total of 153 sera samples (n=63 cases/30 benign disease controls/60 healthy controls). Sensitivities at 95% specificity were calculated and a classifier for the detection of high-grade serous ovarian cancer was constructed. RESULTS: We identified 11-TAAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) that distinguished high-grade serous ovarian cancer cases from healthy controls with a combined 45% sensitivity at 98% specificity. CONCLUSION: These are potential circulating biomarkers for the detection of serous ovarian cancer, and warrant confirmation in larger clinical cohorts.
Authors: Xiaoju Wang; Jianjun Yu; Arun Sreekumar; Sooryanarayana Varambally; Ronglai Shen; Donald Giacherio; Rohit Mehra; James E Montie; Kenneth J Pienta; Martin G Sanda; Philip W Kantoff; Mark A Rubin; John T Wei; Debashis Ghosh; Arul M Chinnaiyan Journal: N Engl J Med Date: 2005-09-22 Impact factor: 91.245
Authors: Jie Wang; Jonine D Figueroa; Garrick Wallstrom; Kristi Barker; Jin G Park; Gokhan Demirkan; Jolanta Lissowska; Karen S Anderson; Ji Qiu; Joshua LaBaer Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-12 Impact factor: 4.254
Authors: Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates Journal: Gynecol Oncol Date: 2008-10-12 Impact factor: 5.482
Authors: Benjamin A Katchman; Rodrigo Barderas; Rizwan Alam; Diego Chowell; Matthew S Field; Laura J Esserman; Garrick Wallstrom; Joshua LaBaer; Daniel W Cramer; Michael A Hollingsworth; Karen S Anderson Journal: Proteomics Clin Appl Date: 2016-05-17 Impact factor: 3.494
Authors: Garnet L Anderson; Martin McIntosh; Lieling Wu; Matt Barnett; Gary Goodman; Jason D Thorpe; Lindsay Bergan; Mark D Thornquist; Nathalie Scholler; Nam Kim; Kathy O'Briant; Charles Drescher; Nicole Urban Journal: J Natl Cancer Inst Date: 2009-12-30 Impact factor: 13.506
Authors: Ian J Jacobs; Usha Menon; Andy Ryan; Aleksandra Gentry-Maharaj; Matthew Burnell; Jatinderpal K Kalsi; Nazar N Amso; Sophia Apostolidou; Elizabeth Benjamin; Derek Cruickshank; Danielle N Crump; Susan K Davies; Anne Dawnay; Stephen Dobbs; Gwendolen Fletcher; Jeremy Ford; Keith Godfrey; Richard Gunu; Mariam Habib; Rachel Hallett; Jonathan Herod; Howard Jenkins; Chloe Karpinskyj; Simon Leeson; Sara J Lewis; William R Liston; Alberto Lopes; Tim Mould; John Murdoch; David Oram; Dustin J Rabideau; Karina Reynolds; Ian Scott; Mourad W Seif; Aarti Sharma; Naveena Singh; Julie Taylor; Fiona Warburton; Martin Widschwendter; Karin Williamson; Robert Woolas; Lesley Fallowfield; Alistair J McGuire; Stuart Campbell; Mahesh Parmar; Steven J Skates Journal: Lancet Date: 2015-12-17 Impact factor: 79.321
Authors: Shadi Ferdosi; Douglas S Rehder; Paul Maranian; Erik P Castle; Thai H Ho; Harvey I Pass; Daniel W Cramer; Karen S Anderson; Lei Fu; David E C Cole; Tao Le; Xifeng Wu; Chad R Borges Journal: J Proteome Res Date: 2017-11-21 Impact factor: 4.466
Authors: Rudolf Kaaks; Renée Turzanski Fortner; Anika Hüsing; Myrto Barrdahl; Marika Hopper; Theron Johnson; Anne Tjønneland; Louise Hansen; Kim Overvad; Agnès Fournier; Marie-Christine Boutron-Ruault; Marina Kvaskoff; Laure Dossus; Mattias Johansson; Heiner Boeing; Antonia Trichopoulou; Vassiliki Benetou; Carlo La Vecchia; Sabina Sieri; Amalia Mattiello; Domenico Palli; Rosario Tumino; Giuseppe Matullo; N Charlotte Onland-Moret; Inger T Gram; Elisabete Weiderpass; Maria-Jose Sánchez; Carmen Navarro Sanchez; Eric J Duell; Eva Ardanaz; Nerea Larranaga; Eva Lundin; Annika Idahl; Karin Jirström; Björn Nodin; Ruth C Travis; Elio Riboli; Melissa Merritt; Dagfinn Aune; Kathryn Terry; Daniel W Cramer; Karen S Anderson Journal: Int J Cancer Date: 2018-03-08 Impact factor: 7.396
Authors: Laura C Hurley; Nancy K Levin; Madhumita Chatterjee; Jasmine Coles; Shlomo Muszkat; Zachary Howarth; Gregory Dyson; Michael A Tainsky Journal: Cancer Biomark Date: 2020 Impact factor: 4.388